As one of only 10 practices in the UK offering LipiView and Lipiflow treatments, BBR Optometry is looking forward to working with Johnson & Johnson, the global leader in eye health, following its acquisition of TearScience.
Ashley McEvoy, Company Group Chairman at Johnson & Johnson, said: “The acquisition of medical device manufacturer TearScience, dedicated to evaluating meibomian gland health and treating Meibomian Gland Dysfunction (MGD), the leading cause of Dry Eye, is another step in Johnson & Johnson Vision’s strategy to become a global leader in eye health.
“Since debuting the world’s first disposable soft contact lens in 1987, Johnson & Johnson Vision Care, Inc. has been helping patients see better through their world-leading ACUVUE® Brand Contact Lenses portfolio.
"Dry Eye is too often the culprit of why patients drop out of contact lenses or why they may have a less than optimal outcome from their cataract surgery.
“The medical device technologies from TearScience will allow us to address the main underlying cause of Dry Eye, giving us a mechanical solution to a mechanical problem," he added.
Nick Rumney, BBR chairman, said: “Dry Eye impacts an estimated 340 million people globally, and MGD, a chronic, progressive condition that can range from mild to severe pain, is the leading cause, which is why we have now opened a dedicated Tear Clinic here in Hereford.
“I am delighted that we are one of the few practices in the UK that are able to offer TearScience technologies Lipiview and Lipiflow which allow us to evaluate meibomian gland health and treat MGD.
“We are now looking forward to developing this relationship and service to patients now these treatments have the backing of Johnson & Johnson,” he added.